Reviewing OpGen (OPGN) & PotNetwork (POTN)

Share on StockTwits

OpGen (NASDAQ:OPGN) and PotNetwork (OTCMKTS:POTN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.

Institutional & Insider Ownership

5.5% of OpGen shares are owned by institutional investors. Comparatively, 0.0% of PotNetwork shares are owned by institutional investors. 7.1% of OpGen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility and Risk

OpGen has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, PotNetwork has a beta of 3.53, suggesting that its share price is 253% more volatile than the S&P 500.


This table compares OpGen and PotNetwork’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
OpGen -453.73% -232.38% -119.08%
PotNetwork N/A N/A N/A

Earnings and Valuation

This table compares OpGen and PotNetwork’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OpGen $2.95 million 1.62 -$13.37 million ($2.22) -0.25
PotNetwork N/A N/A N/A N/A N/A

PotNetwork has lower revenue, but higher earnings than OpGen.

Analyst Recommendations

This is a summary of current recommendations and price targets for OpGen and PotNetwork, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OpGen 0 0 2 0 3.00
PotNetwork 0 0 0 0 N/A

OpGen presently has a consensus price target of $4.15, indicating a potential upside of 650.45%. Given OpGen’s higher probable upside, analysts clearly believe OpGen is more favorable than PotNetwork.


OpGen beats PotNetwork on 5 of the 9 factors compared between the two stocks.

About OpGen

OpGen, Inc., a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel in vitro diagnostic test designed to detect bacterial nucleic acids; and QuickFISH and PNA FISH products, which are FDA-cleared and CE-marked diagnostic test designed to detect antimicrobial- resistant pathogens. It also provides Acuitas MDRO Gene Test, Acuitas CR Elite Test, and Acuitas Resistome Test that are CLIA lab-based tests, which provide a profile of MDRO resistant genes for surveillance and response to outbreaks. In addition, the company offers Acuitas Lighthouse bioinformatics systems, which are cloud-based HIPAA compliant bioinformatics offerings that combine clinical lab test results with patient and hospital information, and provide analytics to enable manage MDROs in the hospital and patient care environment. Further, it engages in the development of Acuitas Rapid Test designed to detect urinary tract infection. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.

About PotNetwork

PotNetwork Holdings, Inc, through its subsidiary, First Capital Venture Co., engages in the research, development, and sale of hemp-derived CBD oil products. It also engages in the pre-owned auto dealership business. The company sells its products through distributors and resellers, as well as through its Website. The company was formerly known as SND Auto Group Inc. and changed its name to PotNetwork Holdings, Inc in March 2017. PotNetwork Holdings, Inc is based in Fort Lauderdale, Florida.

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with's FREE daily email newsletter.